Sign In
Buy FEMY
$2.86
-0.0500 (-1.72%)
At Close: Jul 31, 2026
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
11:06am, Thursday, 02'nd May 2024
Femasys (FEMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ATLANTA, April 18, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-offi
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
04:05pm, Thursday, 28'th Mar 2024
Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 Following FDA Clearance of FemaSeed®, Company Secures C
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
09:00am, Thursday, 21'st Mar 2024
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
08:15am, Wednesday, 20'th Mar 2024
-- In the severe male factor cohort, findings show 24% of women became pregnant after FemaSeed -- -- FemaSeed pregnancy rate by cycle was more than double historic intrauterine insemination (IUI) rate
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
09:00am, Wednesday, 06'th Mar 2024
-- Paving the way forward for the broader commercial availability of FemaSeed, an accessible, safe, and cost effective alternative to IVF -- -- Ongoing uncertainty following recent Alabama Supreme Cou
Femasys' FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
09:00am, Wednesday, 28'th Feb 2024
-- Femasys readies for the commercial launch of FemaSeed ® in the U.S. amidst the uncertainty following the Alabama Supreme Court Ruling on how to handle embryos used for in vitro fertilization (IVF)
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
08:30am, Tuesday, 06'th Feb 2024
-- Seasoned sales and marketing executive with 25 years of experience leading public and private healthcare companies throughout various stages of commercialization will lead commercial launch of Fema
ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessi
- University of Utah Hospital, Lori Gawron, M.D. of the Obstetrics and Gynecology (OB/GYN) Department, was an instrumental investigator in Femasys' earlier FemBloc study -
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
08:30am, Friday, 15'th Dec 2023
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second academic center to participate in the FemBloc pivotal trial since e
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
08:30am, Thursday, 30'th Nov 2023
-- Thought leader from top-ranked academic gynecology program to lead clinical and medical affairs at Femasys -- -- Thought leader from top-ranked academic gynecology program to lead clinical and medi
Femasys: A Women's Health Medical Devices Company Ready To Turn The Corner
08:40am, Tuesday, 28'th Nov 2023
Femasys is a medical device company that offers a suite of minimally invasive reproductive health products for women. The company recently received clearance for its FemaSeed product and plans to laun
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
08:30am, Tuesday, 28'th Nov 2023
- Topline results from FemaSeed ® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 - ATLANTA, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
08:30am, Wednesday, 15'th Nov 2023
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”)
